- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: Plasmacytoid dendritic cells.
Displaying page 1 of 1.
EudraCT Number: 2010-023757-11 | Sponsor Protocol Number: myDC/pDCinstageIIImelanoma | Start Date*: 2014-11-06 |
Sponsor Name:Radboud University Nijmegen Medical Centre | ||
Full Title: Myeloid and plasmacytoid blood dendritic cells for immunotherapy of stage III melanoma patients scheduled for radical lymph node dissection | ||
Medical condition: melanoma patients with regional lymph node metastases (stage III) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-002531-29 | Sponsor Protocol Number: NaturalDCformCRPC | Start Date*: 2014-10-30 |
Sponsor Name:Radboud University Medical Centre Nijmegen | ||
Full Title: A randomized phase IIa study: natural dendritic cells for immunotherapy of chemo-naive metastatic castration-resistant prostate cancer patients | ||
Medical condition: Asymptomatic or minimally symptomatic, chemo-naive mCRPC patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000709-10 | Sponsor Protocol Number: UKM12_0026 | Start Date*: 2014-12-19 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential | |||||||||||||
Medical condition: relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001327-23 | Sponsor Protocol Number: ITP0815 | Start Date*: 2015-06-26 | |||||||||||
Sponsor Name:Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto | |||||||||||||
Full Title: Eltrombopag as Second line Therapy in adult patients with primary Immune Thrombocytopenia (ESTIT study) in an attempt to achieve long-term remission: a single arm multicenter phase II clinical and ... | |||||||||||||
Medical condition: Primary Immune Thrombocytopenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000579-10 | Sponsor Protocol Number: PEANUT | Start Date*: 2019-03-20 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: An open label, single-arm, phase 2 study of pembrolizumab and nanoparticle albumin-bound paclitaxel in patients with metastatic urothelial carcinoma after chemotherapy failure; the PEANUT study | |||||||||||||
Medical condition: Advanced or metastatic urothelial carcinoma of the bladder or urinary tract relapsed or refractory to chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001543-94 | Sponsor Protocol Number: AML2020 | Start Date*: 2020-12-15 | ||||||||||||||||
Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | ||||||||||||||||||
Full Title: Tagraxofusp in Patients with CD123+ or with Blastic Plasmacytoid Dendritic Cell Neoplasm Immunophenotype-like Acute Myeloid Leukemia. | ||||||||||||||||||
Medical condition: Acute Myeloid Leukemia CD123 + or with BPDCN immunophenotype | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003554-41 | Sponsor Protocol Number: UTA2-1DC | Start Date*: 2016-03-15 | ||||||||||||||||||||||||||
Sponsor Name:VU University Medical Center | ||||||||||||||||||||||||||||
Full Title: A phase I/II “minor histocompatibility antigen UTA2-1 loaded, PD-L silenced Dendritic cell vaccination trial after allogeneic Stem Cell Transplantation to improve the safety and efficacy of Donor ... | ||||||||||||||||||||||||||||
Medical condition: Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), non Hodgkin lymphoma (nHL)(any grade), Hodgkin’s lymphoma (HL). | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000827-94 | Sponsor Protocol Number: U-DANCE-anti-AML | Start Date*: 2016-09-08 | ||||||||||||||||
Sponsor Name:UMC Utrecht | ||||||||||||||||||
Full Title: A phase I/II post cord blood HCT dendritic cells vaccination trial directed against WT1 for pediatric acute myeloid leukemia: the U-DANCE-anti-AML trial | ||||||||||||||||||
Medical condition: AML: Acute Myeloid leukemia/ cancer of blood and bone marrow | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Not Authorised) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002752-33 | Sponsor Protocol Number: NL.66760 | Start Date*: 2019-01-17 | ||||||||||||||||||||||||||
Sponsor Name:VU University Medical Center | ||||||||||||||||||||||||||||
Full Title: A phase I/II trial towards the safety and efficacy of preemptive vaccination with PD-L silenced, minor histocompatibility antigen UTA2-1 peptide-loaded Dendritic Cells after Allogeneic Stem Cell Tr... | ||||||||||||||||||||||||||||
Medical condition: Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Non hodgkin lymphoma (any grade), Acute myeloid leukemia (AML) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002850-26 | Sponsor Protocol Number: NL72928.078.20 | Start Date*: 2020-07-20 | |||||||||||||||||||||
Sponsor Name:Albert Schweitzer Hospital | |||||||||||||||||||||||
Full Title: Vaccination response to pneumococcal antigen as novel predictor for successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: the vaccinSTOP study. | |||||||||||||||||||||||
Medical condition: Chronic myeloid leukemia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000962-14 | Sponsor Protocol Number: CCM-RNT-202101 | Start Date*: 2021-07-02 | |||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
Full Title: A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus | |||||||||||||
Medical condition: Systemic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017432-40 | Sponsor Protocol Number: MGN1703-C02 | Start Date*: 2010-04-13 | |||||||||||
Sponsor Name:MOLOGEN AG | |||||||||||||
Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-Center Clinical Study to Evaluate Efficacy and Safety of a Maintenance Therapy with Immunomodulator MGN1703 in Patients with Advanced ... | |||||||||||||
Medical condition: Patients with advanced colorectal carcinoma (AJCC Stage IV) with disease control after initial first-line therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Prematurely Ended) GB (Completed) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000847-25 | Sponsor Protocol Number: EMR63325-013 | Start Date*: 2011-07-04 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A multi-center, randomized, open-label, mechanism of action trial on the biological effects of the therapeutic cancer vaccine Stimuvax® (L-BLP25) in rectal cancer subjects undergoing neoadjuvant ch... | |||||||||||||
Medical condition: Rectal cancer subjects undergoing neoadjuvant chemoradiotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) PT (Completed) DE (Completed) NL (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002382-19 | Sponsor Protocol Number: PDC-LUNG-101 | Start Date*: 2019-06-13 | |||||||||||
Sponsor Name:PDC*line Pharma SAS | |||||||||||||
Full Title: An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, asso... | |||||||||||||
Medical condition: Non-small-cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
